Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Lane HC, Beigel J, Dodd LE; Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members. Singh K, et al. J Infect Dis. 2024 Apr 24:jiae198. doi: 10.1093/infdis/jiae198. Online ahead of print. J Infect Dis. 2024. PMID: 38657001
Epidemiological trends and clinical outcomes of cryptococcosis in a medically insured population in the United States: a claims-based analysis from 2017 to 2019.
Chastain DB, Zhang Q, Chen X, Young HN, Franco-Paredes C, Tuells J, Thompson GR 3rd, Henao-Martínez AF. Chastain DB, et al. Among authors: thompson gr 3rd. Ther Adv Infect Dis. 2024 Apr 18;11:20499361241244967. doi: 10.1177/20499361241244967. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 38645299 Free PMC article.
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
Hoenigl M, Arastehfar A, Arendrup MC, Brüggemann R, Carvalho A, Chiller T, Chen S, Egger M, Feys S, Gangneux J-P, Gold JAW, Groll AH, Heylen J, Jenks JD, Krause R, Lagrou K, Lamoth F, Prattes J, Sedik S, Wauters J, Wiederhold NP, Thompson GR 3rd. Hoenigl M, et al. Among authors: thompson gr 3rd. Clin Microbiol Rev. 2024 Apr 11:e0007423. doi: 10.1128/cmr.00074-23. Online ahead of print. Clin Microbiol Rev. 2024. PMID: 38602408 Review.
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
Locke JB, Pillar CM, Castanheira M, Carvalhaes CG, Andes D, Aram JA, Andrzejewski C, Bartizal K, Das AF, Sandison T, Thompson GR 3rd, Pappas PG. Locke JB, et al. Among authors: thompson gr 3rd. Antimicrob Agents Chemother. 2024 May 2;68(5):e0158423. doi: 10.1128/aac.01584-23. Epub 2024 Mar 25. Antimicrob Agents Chemother. 2024. PMID: 38526046 Free PMC article. Clinical Trial.
Reply to Williams et al.
Nguyen MH, Ostrosky-Zeichner L, Pappas PG, Walsh TJ, Bubalo J, Alexander BD, Miceli MH, Jiang J, Song Y, Thompson GR 3rd. Nguyen MH, et al. Among authors: thompson gr 3rd. Open Forum Infect Dis. 2024 Mar 8;11(3):ofae134. doi: 10.1093/ofid/ofae134. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38524232 Free PMC article. No abstract available.
561 results